Gigli I, Kaplan A P, Austen K F
J Exp Med. 1971 Dec 1;134(6):1466-84. doi: 10.1084/jem.134.6.1466.
An activity designated Kf can be separated from human serum and shown to give a 100-300% enhancement in the hemolytic activity of fully activated, fractionated C1. The enhancement of C1 activity is not because of activation of precursor C1 and it is not attributable to an effect on C1 binding. EAC42 or EAC4 intermediates interacted with C1Kf exhibit a greater T(max) and shorter Z(max) than when such intermediates are reacted with the same number of hemolytic units of C1. C3 consumption by the EAC1Kf42 intermediate greatly exceeds that of the EAC142 intermediate produced from the same EAC4 cells by comparable inputs of the other two complement components. Taken together, these findings suggest that Kf-treated C1 achieves more efficient utilization of C4 and C2 to create a larger number of 42 sites as appreciated on the intermediates by shorter T(max) and a greater Z(max), and an increased capacity to utilize C3. The capacity of Kf to enhance C1 upon introduction into whole serum of a patient with hereditary angioedema (HAE) in a manner comparable to its effect on fractionated C1 suggests that the effect of Kf may be pertinent to certain pathophysiologic conditions of man.
一种被命名为Kf的活性物质可从人血清中分离出来，并且已证明它能使完全活化的、分级分离的C1的溶血活性提高100% - 300%。C1活性的增强并非由于前体C1的激活，也不归因于对C1结合的影响。与C1Kf相互作用的EAC42或EAC4中间体，与用相同数量溶血单位的C1与之反应时相比，表现出更大的T(max)和更短的Z(max)。EAC1Kf42中间体消耗的C3大大超过由相同的EAC4细胞通过其他两种补体成分的相当投入所产生的EAC142中间体。综上所述，这些发现表明，经Kf处理的C1能更有效地利用C4和C2，以产生更多数量的42位点，这在中间体上表现为更短的T(max)和更大的Z(max)，以及利用C3的能力增强。Kf以与其对分级分离的C1的作用相当的方式引入遗传性血管性水肿（HAE）患者的全血清中时增强C1的能力表明，Kf的作用可能与人类的某些病理生理状况相关。
